475488-34-7 Usage
Uses
Used in Pharmaceutical Industry:
7-[Trans-3-(1-Azetidinylmethyl)cyclobutyl]-5-[3-(phenylmethoxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine is used as a pharmaceutical candidate for the development of new medications due to its ability to interact with biological systems. Its unique molecular structure, which includes cyclobutyl, pyrimidin, and amine groups, may contribute to its efficacy in treating various medical conditions.
Further applications and uses of 7-[Trans-3-(1-Azetidinylmethyl)cyclobutyl]-5-[3-(phenylmethoxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine would depend on the outcomes of ongoing research and testing, which will help to elucidate its specific properties and potential therapeutic benefits. As the compound's characteristics are better understood, it may find additional uses in different areas of the pharmaceutical industry, such as drug delivery systems, targeted therapies, or as a component in combination treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 475488-34-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,7,5,4,8 and 8 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 475488-34:
(8*4)+(7*7)+(6*5)+(5*4)+(4*8)+(3*8)+(2*3)+(1*4)=197
197 % 10 = 7
So 475488-34-7 is a valid CAS Registry Number.
475488-34-7Relevant academic research and scientific papers
A concise synthesis of a novel insulin-like growth factor i receptor (IGF-IR) inhibitor
Slade, Joel,Bajwa, Joginder,Liu, Hui,Parker, David,Vivelo, James,Chen, Guang-Pei,Calienni, John,Villhauer, Edwin,Prasad, Kapa,Repic, Oljan,Blacklock, Thomas J.
, p. 825 - 835 (2012/12/30)
An efficient synthesis of a potent insulin-like growth factor I receptor (IGF-IR) inhibitor AEW541 (1) is described. The key step in the synthesis is the cis-selective reductive animation of cyclobutanone, which sets up the desired 1,3-stereochemistry of the cyclobutane ring. The amino group thus generated is used as a handle to build the pyrrolopyrimidine ring. The final step resulting in 1 is accomplished by alkylation of in situ generated mesylate with azetidine.
